Insider · CIK 0001604076
Ronald E Bruehlman
Files at IQV (IQVIA HOLDINGS INC.), GDRX (GoodRx Holdings, Inc.). First filing -, latest -.
Ronald E Bruehlman files SEC Form 4 as director and officer at IQV (IQVIA HOLDINGS INC.), and also at GDRX (GoodRx Holdings, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Ronald E Bruehlman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | GDRX GoodRx Holdings, Inc. | AGrant or award Class A Common Stock | +73,434 | $0.00 | $0 | 207,352 | Jun 17, 2026 |
| May 27, 2026 | GDRX GoodRx Holdings, Inc. | AGrant or award Class A Common Stock | +4,642 | $0.00 | $0 | 133,918 | May 29, 2026 |
| Feb 8, 2026 | IQV IQVIA HOLDINGS INC. | AGrant or award Common Stock | +16,335 | $0.00 | $0 | 50,904 | Feb 10, 2026 |
| Feb 8, 2026 | IQV IQVIA HOLDINGS INC. | FTax withholding Common Stock | -6,801 | $187.49 | $1.3M | 44,103 | Feb 10, 2026 |
| Jan 1, 2026 | GDRX GoodRx Holdings, Inc. | AGrant or award Class A Common Stock | +18,251 | $0.00 | $0 | 129,276 | Jan 5, 2026 |
| Nov 8, 2025 | GDRX GoodRx Holdings, Inc. | MOption exercise Class A Common Stock | +21,691 | - | - | 111,025 | Nov 10, 2025 |
| Nov 8, 2025 | GDRX GoodRx Holdings, Inc. | MOption exercise Deferred Stock Unitderivative | -21,691 | $0.00 | $0 | 43,384 | Nov 10, 2025 |
| Jun 3, 2025 | GDRX GoodRx Holdings, Inc. | AGrant or award Class A Common Stock | +57,050 | $0.00 | $0 | 89,334 | Jun 4, 2025 |
| Feb 10, 2025 | IQV IQVIA HOLDINGS INC. | FTax withholding Common Stock | -907 | $206.97 | $188k | 34,569 | Feb 12, 2025 |
| Jan 28, 2025 | IQV IQVIA HOLDINGS INC. | AGrant or award Common Stock | +6,286 | $0.00 | $0 | 37,677 | Jan 30, 2025 |
| Jan 28, 2025 | IQV IQVIA HOLDINGS INC. | FTax withholding Common Stock | -2,201 | $203.43 | $448k | 35,476 | Jan 30, 2025 |
| Jan 28, 2025 | IQV IQVIA HOLDINGS INC. | AGrant or award Stock Appreciation Rightderivative | +31,603 | $0.00 | $0 | 31,603 | Jan 30, 2025 |
| Jan 1, 2025 | GDRX GoodRx Holdings, Inc. | AGrant or award Class A Common Stock | +10,653 | $0.00 | $0 | 32,284 | Jan 3, 2025 |
| Nov 8, 2024 | GDRX GoodRx Holdings, Inc. | AGrant or award Class A Common Stock | +1,128 | $0.00 | $0 | 1,128 | Nov 12, 2024 |
| Nov 8, 2024 | GDRX GoodRx Holdings, Inc. | AGrant or award Class A Common Stock | +20,503 | $0.00 | $0 | 21,631 | Nov 12, 2024 |
| Nov 8, 2024 | GDRX GoodRx Holdings, Inc. | AGrant or award Deferred Stock Unitderivative | +65,075 | $0.00 | $0 | 65,075 | Nov 12, 2024 |
Questions about Ronald E Bruehlman
Answered from the filings on this page, as of the latest one.
Is Ronald E Bruehlman buying or selling?
Ronald E Bruehlman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Ronald E Bruehlman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ronald E Bruehlman has 0.
Where does Ronald E Bruehlman file Form 4?
Ronald E Bruehlman has filed Form 4 at IQV (IQVIA HOLDINGS INC.) as See Remarks; GDRX (GoodRx Holdings, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.